Advertisement

Levodopa reverses gait asymmetries related to anhedonia and magical ideation

  • C. MohrEmail author
  • T. Landis
  • H. S. Bracha
  • M. Fathi
  • P. Brugger
ORIGINAL PAPER

Abstract

Animals and men turn preferentially away from the hemisphere with the more active dopamine (DA) system. Consistent with the idea of a right–hemispheric hyperdopaminergia in schizophrenia, a leftsided turning bias was described for unmedicated psychotic patients. We investigated the modulating role of DA and schizophrenia–like thought on whole–body turns in a controlled double–blind study. The number of veers to either side when walking blindfolded straight ahead (20 meter) was assessed in 40 healthy righthanded men (20 men received levodopa, the remaining participants placebo). Side preferences were analyzed in terms of individuals’ positive (Magical Ideation, MI) and negative (Physical Anhedonia, PhysAn) schizotypal features. In the placebo group, increasing MI scores were related to increasing left–sided veering and increasing PhysAn scores were related to increasing right–sided veering. In the levodopa group, this relationship between preferred veering side and type of schizotypy was reversed. The finding in the placebo group suggests an association between MI and a relative right–hemispheric hyperdopaminergia. Unexpectedly, levodopa did not enhance this veering bias, but reversed it, suggesting that psychosis–protective mechanisms exist in the healthy positive “schizotypic” brain. Also unexpectedly, levodopa made “anhedonics” veer like “magics” after placebo, suggesting that DA agonists suppress negative schizotypal symptoms.

Key words

dopamine asymmetry hemispheres schizotypy turning neuropharmacology 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761–767PubMedGoogle Scholar
  2. 2.
    Andreasen NC (1995) Symptoms, signs, and diagnosis of schizophrenia. Lancet 346:477–481CrossRefPubMedGoogle Scholar
  3. 3.
    Angrist B, Peselow E, Rubinstein M, Wolkin A, Rotrosen J (1985) Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology 85:277–283Google Scholar
  4. 4.
    Barnett KJ, Corballis MC (2002) Ambidexterity and magical ideation. Laterality 7:75–84PubMedGoogle Scholar
  5. 5.
    Bracha HS, Livingston RL, Clothier J, Linington BB, Karson CN (1993) Correlation of severity of psychiatric patients’ delusions with right hemispatial inattention (left-turning behavior). Am J Psychiatry 150:330–332PubMedGoogle Scholar
  6. 6.
    Bracha HS, Shults C, Glick SD, Kleinman JE (1987) Spontaneous asymmetric circling behavior in hemi-parkinsonism: a human equivalent of the lesioned-circling rodent behavior. Life Sci 40:1127–1130CrossRefPubMedGoogle Scholar
  7. 7.
    Bracha HS (1989) Is there a right hemi-hyper-dopaminergic psychosis? Schizophr Res 2:317–324CrossRefPubMedGoogle Scholar
  8. 8.
    Brown AS, Gershon S (1993) Dopamine and Depression. J Neural Transm 91:75–109Google Scholar
  9. 9.
    Brugger P, Graves RE (1997) Right hemispatial inattention and magical ideation. Eur Arch Psychiatry Clin Neurosci 247:55–57PubMedGoogle Scholar
  10. 10.
    Campbell JJ (2000) Neuropsychiatric assessment. In: Coffey CE, Cummings JL (eds) Textbook of Geriatric Neuropsychiatry, 2nd ed. American Psychiatric Press, Washington, D.C., pp 109–124 Google Scholar
  11. 11.
    Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC (1994) Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol 103:171–183PubMedGoogle Scholar
  12. 12.
    Chapman LJ, Chapman JP, Raulin ML (1976) Scales for physical and social anhedonia. J Abnorm Psychol 85:374–382CrossRefPubMedGoogle Scholar
  13. 13.
    Chapman LJ, Chapman JP (1987) The measurement of handedness. Brain Cogn 6:175–183CrossRefPubMedGoogle Scholar
  14. 14.
    Chapman LJ, Edell WS, Chapman JP (1980) Physical anhedonia, perceptual aberration, and psychosis proneness. Schizophr Bull 6:639–653PubMedGoogle Scholar
  15. 15.
    Claridge GS, Clark KH, Beech AR (1992) Lateralization of the ‘negative priming’ effect: relationships with schizotypy and with gender. Br J Psychol 83:13–23PubMedGoogle Scholar
  16. 16.
    Daniel DG,Weinberger DR, Jones DW,Zigun JR,Coppola R, Handel S, Bigelow LB, Goldberg TE, Berman KF, Kleinman JE (1991) The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 11:1907–1917Google Scholar
  17. 17.
    Davidson M, Davis KL (1988) A comparison of plasma homovanillic acid concentration in schizophrenic patients and normal controls. Arch Gen Psychiatry 45:561–563PubMedGoogle Scholar
  18. 18.
    Davidson M, Keefe RS, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL (1987) L-dopa challenge and relapse in schizophrenia. Am J Psychiatry 144:934–938PubMedGoogle Scholar
  19. 19.
    Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474–1486PubMedGoogle Scholar
  20. 20.
    Eckblad M, Chapman LJ (1983) Magical ideation as an indicator of schizotypy. J Consult Clin Psychol 51:215–225CrossRefPubMedGoogle Scholar
  21. 21.
    Garety P, Wessely S (1994) The assessment of positive symptoms. In: Barnes TRE, Nelson HE (eds) The Assessment of Psychoses. A Practical Handbook. Chapman and Hall, London, England, pp 21–39Google Scholar
  22. 22.
    Gasser UE, Jorga K, Crevoisier C, Hovens SE, van Giersbergen PL (1999) COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson’s disease. Eur Neurol 41:206–211Google Scholar
  23. 23.
    Glick SD, Ross DA, Hough LB (1982) Lateral asymmetry of neurotransmitters in human brain. Brain Res 234:53–63CrossRefPubMedGoogle Scholar
  24. 24.
    Gooding DC, Kwapil TR, Tallent KA (1999) Wisconsin Card Sorting Test deficits in schizotypic individuals. Schizophr Res 40:201–209CrossRefPubMedGoogle Scholar
  25. 25.
    Gooding DC, Miller MD, Kwapil TR (2000) Smooth pursuit eye tracking and visual fixation in psychosis-prone individuals. Psychiatry Res 93:41–54PubMedGoogle Scholar
  26. 26.
    Gray NS, Pickering AD, Snowden RJ, Hemsley DR, Gray JA (2002) The partial reinforcement extinction effect in humans: effects of schizophrenia, schizotypy and low doses of amphetamine. Behav Brain Res 133:333–342PubMedGoogle Scholar
  27. 27.
    Harvey SA, Nelson E, Haller JW, Early TS (1993) Lateralized attentional abnormality in schizophrenia is correlated with severity of symptoms. Biol Psychiatry 33:93–99CrossRefPubMedGoogle Scholar
  28. 28.
    Janowsky DS, Risch C (1979) Amphetamine psychosis and psychotic symptoms. Psychopharmacology 65:73–77Google Scholar
  29. 29.
    Kalaycioglu C, Nalcaci E, Budanur OE, Genc Y, Cicek M (2000) The effect of familial sinistrality on the relation between schizophrenialike thinking and pseudoneglect. Brain Cogn 44:564–576CrossRefPubMedGoogle Scholar
  30. 30.
    Kirrane RM, Siever LJ (2000) New perspective on schizotypal personality disorder. Curr Psychiatry Rep 2:62–66PubMedGoogle Scholar
  31. 31.
    Klein C, Berg P, Rockstroh B, Andresen B (1999) Topography of the auditory P300 in schizotypal personality. Biol Psychiatry 45:1612–1621CrossRefPubMedGoogle Scholar
  32. 32.
    Klein D, Davis J (1969) Diagnosis and Drug Treatment of Psychiatric Disorders. Williams & Wilkins, Baltimore, Md, pp 52–138Google Scholar
  33. 33.
    Kopp B, Wolff M, Hruska C, Reischies FM (2002) Brain mechanisms of visual encoding and working memory in psychometrically identified schizotypal individuals and after acute administration of haloperidol. Psychophysiology 39:459–472CrossRefPubMedGoogle Scholar
  34. 34.
    Kumari V, Cotter PA, Mulligan OF, Checkley SA, Gray NS, Hemsley DR, Thornton JC, Corr PJ, Toone BK, Gray JA (1999) Effects of d-amphetamine and haloperidol on latent inhibition in healthy male volunteers. Psychopharmacology 13:398–405Google Scholar
  35. 35.
    Kwapil T, Miller M, Zinser M, Chapman J, Chapman L (1997) Magical Ideation and social anhedonia as predictors of psychosis proneness: a partial replication. J Abnorm Psychol 106:491–495CrossRefPubMedGoogle Scholar
  36. 36.
    Laruelle M, Abi-Dargham A (1999) Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 13:358–371PubMedGoogle Scholar
  37. 37.
    Levine J, Martine T, Feraro R, Kimhi R, Bracha HS (1997) Medicated chronic schizophrenic patients do not demonstrate left turning asymmetry. Neuropsychobiology 36:22–24PubMedGoogle Scholar
  38. 38.
    Loas G, Boyer P, Legrand A (1999) Anhedonia in the deficit syndrome of schizophrenia. Psychopathology 32:207–219CrossRefPubMedGoogle Scholar
  39. 39.
    Maruff P, Hay D, Malone V, Currie J (1995) Asymmetries in the covert orienting of visual spatial attention in schizophrenia. Neuropsychologia 33:1205–1223Google Scholar
  40. 40.
    Matthysse S (1973) Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed Proc 32:200–205PubMedGoogle Scholar
  41. 41.
    Meehl PE (1962) Schizotaxia, schizotypy, schizophrenia. Am Psychologist 17:827–838Google Scholar
  42. 42.
    Meyer TD, Hautzinger M (1999) Two year stability of psychosis proneness scales and their relationship to personality disorder traits. J Pers Assess 73:472–488CrossRefPubMedGoogle Scholar
  43. 43.
    Mohr C, Bracha HS, Brugger P (2003a) Magical Ideation modulates spatial behavior. J Neuropsychiatry Clin Neurosci 15:168–174Google Scholar
  44. 44.
    Mohr C, Landis T, Bracha HS, Fathi M, Brugger P (2003b) Human locomotion: levodopa keeps you straight. Neurosci Lett 339:115–118CrossRefGoogle Scholar
  45. 45.
    Mohr C, Brugger P, Bracha HS, Landis T, Viaud-Delmon I (2004) Human side preferences in three different whole-body movement tasks. Behav Brain Res 151:321–326CrossRefPubMedGoogle Scholar
  46. 46.
    Mohr C, Landis T, Sandor PS, Fathi M, Brugger P (in press) Nonstereotyped responding in positive schizotypy after a single dose of levodopa. NeuropsychopharmacologyGoogle Scholar
  47. 47.
    Park S, Holzman PS, Lenzenweger MF (1995) Individual differences in spatial working memory in relation to schizotypy. J Abnorm Psychol 104:355–363PubMedGoogle Scholar
  48. 48.
    Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM (1984) Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225:954–957PubMedGoogle Scholar
  49. 49.
    Pizzagalli D, Lehmann D, Gianotti L, Koenig T, Tanaka H, Wackermann J, Brugger P (2000) Brain electric correlates of strong belief in paranormal phenomena: intracerebral EEG source and regional Omega complexity analyses. Psychiatry Res 100:139–154PubMedGoogle Scholar
  50. 50.
    Posner MI, Early TS, Reiman E, Pardo PJ, Dhawan M (1988) Asymmetries in hemispheric control of attention in schizophrenia. Arch Gen Psychiatry 45:814–821PubMedGoogle Scholar
  51. 51.
    Pycock CJ (1983) Experimental model of hemi-Parkinsonism. In: Myslobodsky MS (ed) Hemisyndromes: Psychobiology, Neurology, Psychiatry. Academic Press, New York, USA, pp 69–90Google Scholar
  52. 52.
    Sarkin AJ, Dionisio DP, Hillix WA, Granholm E (1998) Positive and negative schizotypal symptoms relate to different aspects of crossover reaction time task performance. Psychiatry Res 81:241–249CrossRefPubMedGoogle Scholar
  53. 53.
    Scherbarth-Roschmann P, Hautzinger M (1991) Zur psychometrischen Erfassung von Schizotypie: Methodische Überprüfung und erste Validierung von zwei Skalen zur Erfassung von Risikomerkmalen. Z Klin Psychol 20:238–250Google Scholar
  54. 54.
    Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N (2001) Methamphetamine- related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206–1214CrossRefPubMedGoogle Scholar
  55. 55.
    Shaw J, Claridge G, Clark K (2001) Schizotypy and the shift from dextrality: a study of handedness in a large non-clinical sample. Schizophr Res 50:181–189CrossRefPubMedGoogle Scholar
  56. 56.
    Shihabuddin L, Buchsbaum MS, Hazlett EA, Silverman J, New A, Brickman AM, Mitropoulou V, Nunn M, Fleischman MB, Tang C, Siever LJ (2001) Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia. Arch Gen Psychiatry 58:877–884PubMedGoogle Scholar
  57. 57.
    Siever LJ, Amin F, Coccaro EF, Bernstein D, Kavoussi RJ, Kalus O, Horvath TB, Warne P, Davidson M, Davis KL (1991) Plasma homovanillic acid in schizotypal personality disorder. Am J Psychiatry 148:1246–1248PubMedGoogle Scholar
  58. 58.
    Siever LJ, Amin F, Coccaro EF, Trestman R, Silverman J, Horvath TB, Mahon TR, Knott P, Altstiel L, Davidson M, Davis KL (1993) CSF homovanillic acid in schizotypal personality disorder. Am J Psychiatry 150:149–151PubMedGoogle Scholar
  59. 59.
    Siever LJ, Davis KL (2004) The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry 161:398–413CrossRefPubMedGoogle Scholar
  60. 60.
    Szeszko PR, Bilder RM, Dunlop JA, Walder DJ, Lieberman JA (1999) Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biol Psychiatry 45:680–686CrossRefPubMedGoogle Scholar
  61. 61.
    Taylor KI, Zäch P, Brugger P (2002) Why is magical ideation related to leftward deviation on an implicit line bisection task? Cortex 38:247–252PubMedGoogle Scholar
  62. 62.
    Tomer R, Flor-Henry P (1989) Neuroleptics reverse attention asymmetries in schizophrenic patients. Biol Psychiatry 25:852–860CrossRefPubMedGoogle Scholar
  63. 63.
    Tsuang MT, Stone WS, Tarbox SI, Faraone SV (2002) An integration of schizophrenia with schizotypy: identification of schizotaxia and implications for research on treatment and prevention. Schizophr Res 54:169–175CrossRefPubMedGoogle Scholar
  64. 64.
    Van Os J, Verdoux H, Maurice-Tison S, Gay B, Liraud F, Salamon R, Bourgeois M (1999) Self-reported psychosis-like symptoms and the continuum of psychosis. Soc Psychiatry Psychiatr Epidemiol 34:459–463CrossRefPubMedGoogle Scholar
  65. 65.
    Verdoux H, van Os J (2002) Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr Res 54:59–65CrossRefPubMedGoogle Scholar
  66. 66.
    Williams JH, Wellman NA, Geaney DP, Feldon J, Cowen PJ, Rawlins JN (1997) Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology 133:262–268CrossRefPubMedGoogle Scholar

Copyright information

© Steinkopff Verlag 2004

Authors and Affiliations

  • C. Mohr
    • 1
    • 2
    • 3
    Email author
  • T. Landis
    • 1
  • H. S. Bracha
    • 4
  • M. Fathi
    • 5
  • P. Brugger
    • 3
  1. 1.Functional Brain Mapping Laboratory Dept. of Neurology, University Hospital GenevaGeneva 14
  2. 2.Dept. of RehabilitationUniversity Hospital GenevaGenevaSwitzerland
  3. 3.Dept. of NeurologyUniversity Hospital ZurichZurichSwitzerland
  4. 4.Honolulu VA National Centre for PTSDHonoluluUSA
  5. 5.Clinical Chemistry Central LaboratoryUniversity Hospital GenevaGenevaSwitzerland

Personalised recommendations